EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
Giant cell arteritis (GCA), formerly known as Horton's disease, is among the most common diseases from a group of systemic vasculitides; its clinical significance is complemented with the potential involvement of the coronary arteries, aorta, and cranial arteries with development of ischemic op...
Saved in:
| Main Authors: | T. V. Beketova, M. A. Ushakova, N. Yu. Nikishina, A. N. Khelkovskaya-Sergeeva, E. V. Nikolaeva, E. G. Sazhina, T. M. Novoselova, E. L. Nasonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2018-05-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01) -
Tocilizumab in Extracranial Giant-Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
by: Carmen Lasa-Teja, et al.
Published: (2025-01-01) -
The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy
by: E. L. Nasonov, et al.
Published: (2024-12-01) -
The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)